Jacob Bell
New Member
Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia
Author(s) Snider SR, Consroe P.
Journal, Volume, Issue Neurology 1985;35(Suppl):201.
Major outcome(s) Improvement of dyskinesia
Indication Parkinson's disease
Medication Cannabidiol
Route(s) Oral
Dose(s) 100-400 mg
Duration (days)
Participants 1 patient with parkinsonism and secondary dystonia.
Design Uncontrolled case report
Type of publication Medical journal
Abstract
In idiopathic dystonia, the terapeutic effect of marijuana smoking is reported to be comparable to diazepam (C.D. Marsden, in Disorders of Movement, 1981,81). The non-psychoactive cannabis derivative, cannabidiol (CBD), also improves dystonia (Consroe and Snider, in Cannbinoids as Therapeutic Agents, in press). We report the effect of CBD on dystonia secondary to Sinemet in parkinsonism, a disorder thought to be a relative contraindication for cannabinoids (D.Moss et al, Pharmacol Biochem Behav 1981, 1984). The patient, a 42-year- old man with an 8-year history of parkinsonism, developed peak-dose dyskinesia about 4 years ago and action dystonia affecting all limbs more recently. Trihexyphenidyl and bromocriptine each produced only slight improvement. To stable optimal dosages of the three drugs, CBD was added, starting with 100 mg/d and increasing by 100 mg weekly. At 100 to 200 mg/d, there was a decrease in clinical fluctuations and in dyskinesia scores (by 30%) without a significant worsening of the parkinsonism. At 300 to 400 mg/d, there was no further improvement in the dyskinesia, and adverse effects (dizziness, drowsiness, increased Parkinson symptoms) appeared. CBD withdrawal resulted in 3 days of severe generalized dystonia and several weeks of increased sensitivity to Sinemet, suggestive of a �drug holiday� effect.
Source: Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia
Author(s) Snider SR, Consroe P.
Journal, Volume, Issue Neurology 1985;35(Suppl):201.
Major outcome(s) Improvement of dyskinesia
Indication Parkinson's disease
Medication Cannabidiol
Route(s) Oral
Dose(s) 100-400 mg
Duration (days)
Participants 1 patient with parkinsonism and secondary dystonia.
Design Uncontrolled case report
Type of publication Medical journal
Abstract
In idiopathic dystonia, the terapeutic effect of marijuana smoking is reported to be comparable to diazepam (C.D. Marsden, in Disorders of Movement, 1981,81). The non-psychoactive cannabis derivative, cannabidiol (CBD), also improves dystonia (Consroe and Snider, in Cannbinoids as Therapeutic Agents, in press). We report the effect of CBD on dystonia secondary to Sinemet in parkinsonism, a disorder thought to be a relative contraindication for cannabinoids (D.Moss et al, Pharmacol Biochem Behav 1981, 1984). The patient, a 42-year- old man with an 8-year history of parkinsonism, developed peak-dose dyskinesia about 4 years ago and action dystonia affecting all limbs more recently. Trihexyphenidyl and bromocriptine each produced only slight improvement. To stable optimal dosages of the three drugs, CBD was added, starting with 100 mg/d and increasing by 100 mg weekly. At 100 to 200 mg/d, there was a decrease in clinical fluctuations and in dyskinesia scores (by 30%) without a significant worsening of the parkinsonism. At 300 to 400 mg/d, there was no further improvement in the dyskinesia, and adverse effects (dizziness, drowsiness, increased Parkinson symptoms) appeared. CBD withdrawal resulted in 3 days of severe generalized dystonia and several weeks of increased sensitivity to Sinemet, suggestive of a �drug holiday� effect.
Source: Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia
